See more : Société Foncière Lyonnaise (FLY.PA) Income Statement Analysis – Financial Results
Complete financial analysis of KalVista Pharmaceuticals, Inc. (KALV) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of KalVista Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Hunan Changyuan Lico Co.,Ltd. (688779.SS) Income Statement Analysis – Financial Results
- ZERO Co., Ltd. (9028.T) Income Statement Analysis – Financial Results
- Genovate Biotechnology Co., Ltd. (4130.TWO) Income Statement Analysis – Financial Results
- Square Enix Holdings Co., Ltd. (9684.T) Income Statement Analysis – Financial Results
- Encore Wire Corporation (WIRE) Income Statement Analysis – Financial Results
KalVista Pharmaceuticals, Inc. (KALV)
About KalVista Pharmaceuticals, Inc.
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, a plasma kallikrein inhibitor that completed a Phase II clinical trial for the treatment of DME; sebetralstat, which is initiation of the Phase 3 KONFIDENT trial as a potential oral, on-demand therapy for HAE attacks; KVD824, an oral product candidate for the treatment of HAE; and Factor XIIa, an oral inhibitor program which is in preclinical stage targets an enzyme in HAE. The company is headquartered in Cambridge, Massachusetts.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 12.69M | 12.69M | 16.13M | 8.39M | 1.50M | 2.13M | 1.80M | 415.00K | 1.54M |
| Cost of Revenue | 86.17M | 802.00K | 743.00K | 651.00K | 40.19K | 35.02K | 18.24K | 12.67K | 14.66K | 8.29K | 0.00 | 0.00 |
| Gross Profit | -86.17M | -802.00K | -743.00K | 12.04M | 12.65M | 16.09M | 8.38M | 1.49M | 2.12M | 1.80M | 415.00K | 1.54M |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 94.87% | 99.68% | 99.78% | 99.78% | 99.16% | 99.31% | 99.54% | 100.00% | 100.00% |
| Research & Development | 86.17M | 80.28M | 70.17M | 41.29M | 40.19M | 35.02M | 18.24M | 12.67M | 14.66M | 8.29M | 4.23M | 1.96M |
| General & Administrative | 54.28M | 30.60M | 26.45M | 16.64M | 13.03M | 10.93M | 8.86M | 11.18M | 2.65M | 1.61M | 1.40M | 1.41M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 54.28M | 30.60M | 26.45M | 16.64M | 13.03M | 10.93M | 8.86M | 11.18M | 2.65M | 1.61M | 1.40M | 1.41M |
| Other Expenses | -86.17M | 15.64M | 14.72M | 9.93M | 9.83M | 7.68M | 4.39M | 2.33M | 2.03M | 844.00K | -59.00K | 35.00K |
| Operating Expenses | 54.28M | 110.87M | 96.61M | 57.92M | 53.22M | 45.95M | 27.10M | 23.84M | 17.31M | 9.89M | 5.63M | 3.37M |
| Cost & Expenses | 140.45M | 110.87M | 96.61M | 57.92M | 53.22M | 45.95M | 27.10M | 23.84M | 17.31M | 9.89M | 5.63M | 3.37M |
| Interest Income | 0.00 | 2.23M | 1.09M | 903.00K | 1.83M | 1.40M | 82.00K | 36.00K | 50.00K | 19.00K | 2.00K | 1.00K |
| Interest Expense | 0.00 | 0.00 | 1.09M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 405.00K | 256.00K |
| Depreciation & Amortization | 816.00K | 802.00K | 743.00K | 651.00K | 525.00K | 378.00K | 180.00K | 40.00K | 133.00K | 38.00K | 27.00K | 38.00K |
| EBITDA | -134.28M | -92.11M | -81.60M | -45.59M | -40.02M | -29.44M | -18.53M | -22.30M | -15.15M | -8.05M | -5.25M | -1.76M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | -458.89% | -312.48% | -182.87% | -201.94% | -1,573.80% | -788.05% | -446.29% | -1,264.10% | -114.37% |
| Operating Income | -140.45M | -110.87M | -96.61M | -57.92M | -40.53M | -29.82M | -18.71M | -22.34M | -15.18M | -8.09M | -5.22M | -1.83M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | -456.45% | -319.41% | -184.91% | -222.84% | -1,485.31% | -711.72% | -448.39% | -1,256.87% | -119.18% |
| Total Other Income/Expenses | 5.35M | 17.96M | 14.27M | 11.68M | 11.29M | 9.13M | 2.90M | 3.74M | 3.75M | 863.00K | -462.00K | -220.00K |
| Income Before Tax | -135.10M | -92.91M | -82.34M | -46.24M | -29.24M | -20.69M | -15.81M | -18.60M | -11.44M | -7.23M | -5.68M | -2.05M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | -364.41% | -230.42% | -128.31% | -188.29% | -1,236.90% | -536.15% | -400.55% | -1,368.19% | -133.49% |
| Income Tax Expense | -8.45M | -18.05M | -13.83M | -1.75M | -124.00K | 124.00K | -1.33M | -5.11M | -5.41M | -863.00K | 462.00K | 220.00K |
| Net Income | -126.64M | -74.85M | -68.51M | -44.49M | -29.12M | -20.82M | -15.81M | -18.60M | -11.44M | -7.23M | -5.68M | -2.05M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | -350.62% | -229.44% | -129.08% | -188.29% | -1,236.90% | -536.15% | -400.55% | -1,368.19% | -133.49% |
| EPS | -3.44 | -2.68 | -2.80 | -2.33 | -1.64 | -1.38 | -1.53 | -1.92 | -2.40 | -6.17 | -7.83 | -2.83 |
| EPS Diluted | -3.44 | -2.68 | -2.80 | -2.33 | -1.64 | -1.38 | -1.53 | -1.92 | -2.40 | -6.17 | -7.83 | -2.83 |
| Weighted Avg Shares Out | 36.79M | 27.89M | 24.47M | 19.09M | 17.75M | 15.08M | 10.32M | 9.71M | 4.77M | 1.17M | 724.80K | 724.80K |
| Weighted Avg Shares Out (Dil) | 36.79M | 27.89M | 24.47M | 19.09M | 17.75M | 15.08M | 10.32M | 9.71M | 4.77M | 1.17M | 724.80K | 724.80K |
Is it a Good Idea to Invest in KalVista (KALV) Stock Now?
Here we discuss some reasons why investing in KalVista Pharmaceuticals (KALV) stock now may turn out to be a prudent move now.
KalVista Pharmaceuticals to Present at Cantor Global Healthcare Conference
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced it will present at the Cantor Global Healthcare Conference on...
5 Stocks to Buy as Drug Industry Displays Strong Fundamentals
Innovation is expected to continue driving growth in the Medical-Drugs industry. CORT, AUPH, ALPN, KALV and CRDL may prove to be good additions to one's portfolio.
KalVista Pharmaceuticals Reports First Fiscal Quarter Results and Provides Operational Update
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today provided an operational update and released financial results for the first...
Is KalVista Pharmaceuticals (KALV) Stock Outpacing Its Medical Peers This Year?
Here is how KalVista Pharmaceuticals, Inc. (KALV) and Achilles Therapeutics PLC Sponsored ADR (ACHL) have performed compared to their sector so far this year.
KalVista Pharmaceuticals to Present HAE Attack Journey Data at 2023 HAEi Regional Conference EMEA
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced the acceptance of multiple abstracts at the 2023 HAEi...
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced the grant of an inducement award to the Company's recently appointed Chief Commercial Officer, Nicole Sweeny. In connection with Ms. Sweeny's appointment, the compensation committee of KalVista's board...
KalVista Pharmaceuticals Expands Senior Leadership Team with Appointment of Nicole Sweeny as Chief Commercial Officer
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, announced today the appointment of Nicole Sweeny as Chief Commercial Officer....
KalVista Pharmaceuticals Presents New HAE Attack Journey Data at 2023 US HAEA National Summit
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced that it presented data on the hereditary angioedema (HAE)...
KalVista Pharmaceuticals to Present HAE Attack Journey Data at 2023 US HAEA National Summit
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced the acceptance of multiple abstracts at the 2023 US HAEA...
Source: https://incomestatements.info
Category: Stock Reports